Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON47991
NL-OMON47991
Not yet recruiting
Not Applicable

Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility study - ATTRACT

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites35 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLiver CancerPrimary Liver Cell Carcinoma100196541000381610019815

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Liver Cancer
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
35
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Patients diagnosed with autoimmune hepatitis
  • •\- Age: 18 years or older
  • •\- Written informed\-consent

Exclusion Criteria

  • •\- Patients with current use of immune suppressive agents/medication, not other
  • •\- Patients with an immunocompromised medical condition, not other specified
  • •\- Patients who refuse to participate in the study (refusing blood donation)
  • •\- Patients that for medical reasons are judged unfit to donate blood by the
  • •treating physicians

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.head and neck squamous cell carcinomamaligne melanomaskin canceruveal melanoma100300541002765610040900
NL-OMON52657Erasmus MC, Universitair Medisch Centrum Rotterdam20
Not yet recruiting
Phase 1/2
MAGE-C2 TCR T cell therapy
2024-516922-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20
Completed
Phase 1
Adoptive transfer of autologous T cells followed by vaccination with MAGE-A4-derived peptides after chemotherapy for MAGE-A4-expressing advanced cancer patientsHead and neck cancer, Ovarian cancer, Esophageal cancer, Multiple myeloma
JPRN-UMIN000001063Department of Immuno-gene Therapy, Mie University Graduate School of Medicine9
Recruiting
Not Applicable
Evaluation of Transplant-reactive T cells for the Prediction or Diagnosis of Transplant Rejection in Kidney Transplant Recipients (TreaT-Assay)T86.10T86.11T86.12T86.19
DRKS00028707Charité Campus Virchow-Klinikum185
Recruiting
Not Applicable
Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer)melanomaSkin cancer10040900
NL-OMON34342ederlands Kanker Instituut2